Monopar Therapeutics Inc.

NASDAQ:MNPR

Biotechnology

Healthcare
$70.75 +2.45%

+$1.58 today

Market cap
$479.46M
Beta
1.54
P/E (TTM)
-37.6
EPS (TTM)
-$1.76
52W Low $29.18High $105.00

Volume 0.10M

Average 0.17M

MNPR Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Monopar Therapeutics Inc.NASDAQ: MNPR

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit remains negative

Q1 FY2026 gross profit was $0, compared with $0 a year earlier. Trailing-twelve-month gross profit was $0.

Context

  • Gross profit increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Gross Profit vs competitors

How MNPR compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
MNPR Competitors
Gross Profit for MNPR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ZYMEZymeworks Inc.LTM Sep 2026$182.57M USD+35.8%-36.4%68.6%
MGNXMacroGenics, Inc.LTM Mar 2026$109.85M USD+16.2%-9.3%69.9%
ADCTADC Therapeutics S.A.LTM Mar 2026$71.82M USD+2.1%-29.1%90.7%
XNCRXencor, Inc.LTM Jun 2026$45.46M USD-54.8%—43.3%
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$35.49M USD+8840.1%-55.6%101.1%
IPHAInnate Pharma S.A.FY2025€2.79M EUR-77.9%-22.6%100.0%
MNPRMonopar Therapeutics Inc.LTM Mar 2026$0 USD———
ALXOALX Oncology Holdings Inc.LTM Mar 2026-$150K USD+31.8%——
CMPXCompass Therapeutics, Inc.LTM Mar 2026-$738K USD-186.8%——
IMNMImmunome, Inc.LTM Sep 2026-$753K USD+98.1%——
BCYCBicycle Therapeutics plcLTM Mar 2026-$7.53M USD+94.3%+71.2%11.9%
Peer median (excluding MNPR) —+24.0%-25.8%69.9%

Competitors are the stored peer set for MNPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development6.49M7.59M5.6M13.01M9.9B
Selling, General & Admin2.63M2.95M3.23M3.16M6.8B
Operating Expenses9.13M10.54M8.83M16.16M16.7M
Depreciation & Amortization00000
EBITDA(9.1M)(10.52M)(8.4M)(15.59M)(13.72M)
EBITDA Margin—————
Operating Income(9.13M)(10.54M)(8.83M)(16.16M)(16.7M)
Operating Margin—————
Interest Income24.02K21.24K429.04K404.02K2.99M
Interest Expense00000
Other Income / Expenses24.02K21.24K429.04K575.3K2.99M
Income Before Tax(9.1M)(10.52M)(8.4M)(15.59M)(13.72M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(9.1M)(10.52M)(8.4M)(15.59M)(13.72M)
Net Margin—————
EPS (Basic)(0.73)(0.83)(0.58)(1.36)(1.85)
EPS (Diluted)(0.73)(0.83)(0.58)(1.36)(1.85)
Weighted Avg Shares12.47M12.72M14.51M11.44M7.41M
Weighted Avg Shares (Diluted)12.47M12.72M14.51M11.48M7.41M

Monopar Therapeutics Inc.

NASDAQ:MNPR

Intrinsic Alpha fair value

Locked

Current Price

$70.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.